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1  | INTRODUC TION
Schistosomiasis is a water- borne parasitic disease of great pub-
lic health importance mainly in sub- Saharan African countries.1 
Currently, there is a major effort to have schistosome control pro-
grammes in all schistosome endemic countries in Africa.2-4 There is 
a need to understand all of the potential effects and implications of 
schistosome antihelminthic treatment in affected populations. One 
such potential impact of treatment is on the host immune response 
against schistosome parasites.5,6
It is well documented that naturally acquired immunity against 
schistosome infections reduces both prevalence and infection in-
tensity in the older age groups in endemic areas.7,8 However, this 
protective immunity takes years of chronic infection to develop nat-
urally. There are two reasons why anti- schistosome immunity takes 
long to develop, first; the parasite is capable of evading host immu-
nity and second; the host requires a threshold of antigens to mount 
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Summary
Aims: Previous studies have reported that chemotherapy of schistosomiasis by prazi-
quantel in humans boosts protective antibody responses against S mansoni and 
S haematobium. A number of studies have reported schistosome- specific antibody 
levels before and after chemotherapy. Using these reports, a meta- analysis was con-
ducted to identify predictors of population level change in schistosome- specific anti-
body levels after chemotherapy.
Methods and results: Following a systematic review, 92 observations from 26 arti-
cles	published	between	1988	and	2013	were	 included	 in	 this	 study.	Observations	
were grouped by antigen type and antibody isotypes for the classification and re-
gression tree (CART) analysis. The study showed that the change in antibody levels 
was variable: (a) between different human populations and (b) according to the para-
site antigen and antibody isotypes. Thus, while anti- worm responses predominantly 
increased after chemotherapy, anti- egg responses decreased or did not show a sig-
nificant trend. The change in antibody levels depended on a combination of age and 
infection	intensity	for	anti-	egg	IgA,	IgM,	IgG1,	IgG2	and	anti-	worm	IgM	and	IgG.
Conclusion: The study results are consistent with praziquantel treatment boosting 
anti- worm antibody responses. However, there is considerable heterogeneity in 
post- treatment changes in specific antibody levels that is related to host age and pre- 
treatment infection intensity.
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a protective immune response. Schistosome worms have an average 
life span of several years.9-11 The antigens from adult worms only be-
come accessible to the host immune system following praziquantel 
treatment.5,12-14
Praziquantel (PZQ) treatment has been reported to enhance 
host protective immunity by exposing the parasite’s hidden antigens 
in large amounts,5,6,15 and by removing the immunomodulatory ef-
fects of adult worms.16,17 PZQ treatment allows hosts’ immune sys-
tems to recognize schistosome parasite adult worm antigens that 
is required to develop protective immunity.15 In 2001, a review of 
seven field studies reported high levels of heterogeneity in the type 
and magnitude of change in antibody levels after chemotherapy 
between different human populations.18 To date, many potential 
factors have been suggested to explain this variation, such as pre- 
treatment infection intensity,19 level of schistosome endemicity,19 
age,20,21 sex21 and co- infection with human immunodeficiency virus 
(HIV).22 This is important for understanding the consequences of 
the epidemiological transition occurring in populations subject to 
national schistosome control programs through mass drug admin-
istration both for the host and the parasite.23 However, there has 
not been a systematic review of published studies investigating the 
potential determinants of the heterogeneity in post- treatment im-
mune responses. Therefore, the objectives of this study are (a) to 
investigate the pattern of antibody levels change across different 
human populations and (b) to identify host and parasite factors that 
affect the antibody levels change after PZQ treatment in the pop-
ulation levels.
2  | METHODS
2.1 | Systematic review
An electronic literature search was conducted using six data-
bases. Web of Science Core Collection, BIOSIS Citation Index and 
MEDLINE	 all	 of	 which	 were	 searched	 through	 Web	 of	 Science	
(www.webofknowledge.com).	In	addition,	EMBASE,	Global	Health	
and Ovid Medicine were searched through Ovid (ovidsp.tx.ovid.
com).	The	search	terms	were	as	follows:	“schistosom*”	AND	(“anti-
bod*”	OR	“IgA”	OR	“IgE”	OR	“IgM”	OR	“IgG*”)	AND	[“albendazole”	
OR “metrifonate” OR “artesunate” OR “antihelmint*” OR “chem-
otherap*”	OR	 “praziquantel”	OR	 “oxamniquine”	OR	 (“drug”	 AND	
“treatment”)]. This electronic literature search was completed in 
January	2014.	After	removing	duplicates,	a	 total	of	1366	unique	
articles were identified for consideration in the present study. 
Titles and abstracts of articles were screened to exclude those 
that were clearly not relevant. Full texts of potentially relevant 
articles were then reviewed for further selection. Full texts of the 
relevant articles were sourced through the Web of Science, Ovid, 
Google	Scholar	(scholar.google.com),	the	University	of	Edinburgh	
library and the Inter Library Loan of the University of Edinburgh. 
Non-	English	 articles	 were	 included	 in	 this	 study,	 and	 several	
Chinese articles were identified and translated into English by a 
native Chinese speaker for the systematic literature review.
2.2 | Inclusion criteria
An article was included in this study if it met all of the following cri-
teria: (a) human study (either sex), (b) infection with S mansoni and/
or S haematobium diagnosed by parasitological egg count, (c) par-
ticipants treated with PZQ, (d) number of participants reported, (e) 
schistosome- specific antibody levels reported before and after PZQ 
treatment, (f) follow- up study conducted within 14- 180 days after 
PZQ treatment, (g) schistosome worm antigen (WWA: whole worm 
homogenate and/or soluble worm antigen), and/or soluble egg anti-
gen (SEA) used to measure antibody isotype levels, (h) participants 
potentially exposed to schistosome infection for their life- time and/
or longer than 1 year before the study, (i) participants’ ages could be 
categorized as child (0- 10 years old), adolescent (11- 21 years old) or 
adult	(≥21	years	old).
2.3 | Exclusion criteria
Articles were excluded based on the following exclusion criteria: 
(a) participants had a previous history of antihelminthic treatment 
prior to the study participation, (b) participants were treated with 
any antihelminthic drug other than PZQ (eg, oxamniquine), (c) par-
ticipants were specifically selected because of co- infection with 
HIV and/or soil transmitted helminths and/or plasmodium, (d) puri-
fied and/or recombinant schistosome antigens were used to meas-
ure antibody isotype levels, (e) participants were temporary visitors 
to endemic areas (ie, travellers), (f) participants were originally from 
endemic areas but had moved to non- endemic areas prior to the 
study (eg, immigrants), (g) participants were diagnosed with acute 
schistosomiasis, (h) clinical case reports from a single patient.
In schistosomiasis endemic areas, co- infection with soil transmit-
ted helminths is frequently reported.24 These studies were kept in 
the analysis only if they did not specifically select co- infected par-
ticipants. Schistosome- specific antibody isotype levels before (base-
line) and after (follow- up) treatment with PZQ were extracted from 
the selected articles. For those articles that reported results only 
in graphical format, the software DataThief III (2006) was used to 
extract the raw data, whenever the graph format allowed it.
In addition to antibody levels, the following information was 
also extracted from each article: the year of publication, article 
title, names of authors, study area (country, region and village), 
schistosome parasite species, co- infection status, co- infecting 
pathogen species, number of participants, age or age range, sex, 
height, weight, days between the treatment and follow- up, pre- 
and post- treatment infection intensity and prevalence, PZQ dose 
and cure rate. Several articles reported results from multiple dif-
ferent groups of participants in the same study area, such as from 
different age groups. In such cases, the result from each group was 
recorded as a separate observation. For the purpose of classifi-
cation and regression tree (CART) analysis, they were treated as 
independent observations. For articles that reported results from 
multiple follow- up time points, the first follow- up after 14 days 
was selected and included in this study. A total of 92 observations 
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from	26	articles	(published	1988-	2013)	met	all	the	inclusion	criteria	
and were considered for the final meta- analysis (Figure 1, Tables 1, 
Appendix S1 and Table S1).
Potential predictors were selected according to their biological 
importance, as suggested by earlier studies19,21 and if they were 
reported by the majority of articles included in this study. The fol-
lowing predictors were considered: age groups (0- 10 years old, 11- 
21	years	old,	≥21	years	old),	pre-	treatment	 infection	 intensity	 [low	
(S mansoni: 1- 99 eggs/1 g faeces, S haematobium: 1- 49 eggs/10 ml 
urine) or high (S mansoni:	≥100	eggs/1	g	faeces,	S haematobium:	≥50	
eggs/10 mL urine)], schistosome species (S mansoni, S haematobium, 
or co- infection of S mansoni and S haematobium), disease prevalence 
(low/moderate:	 <50%	 or	 high:	 ≥50%),	 and	 days	 between	 chemo-
therapy and follow- up. The “low” infection intensity in the current 
study is equivalent to “light” in the WHO’s infection intensity cate-
gories both for S mansoni and S haematobium. However, “high” infec-
tion intensity is WHO’s “heavy” for S haematobium but “moderate” 
or “heavy” for S mansoni. This was due to the small sample size of 
S mansoni studies: there were only eight observations from four arti-
cles that reported >400 eggs/1 g faeces that is “heavy” infection by 
WHO guideline.
2.4 | Software
Articles identified by the systematic review were recorded using 
Thomson	Reuters	EndNote,	and	the	extracted	data	were	entered	in	
a spreadsheet using Microsoft Excel 2010. B. Tummers, DataThief 
III. 2006 (http://datathief.org/) was used to extract data from pub-
lished graphs. IBM SPSS Statistics Version 21.0 was used for statisti-
cal	analysis.	GraphPad	Software	GraphPad	Prism	version	6.03	was	
used to create graphs.
2.5 | Statistical analysis
The majority of studies included in this study used the enzyme- linked 
immunosorbent assay (ELISA) method to quantify antibody isotype 
levels and reported optical density (OD). However, OD values can-
not be directly compared between studies conducted by different 
research groups.25 Therefore, the outcome variable was catego-
rized according to the direction of change in antibody levels from 
pre- treatment baseline to levels at follow- up. That is, pre- treatment 
and post- treatment antibody isotype levels were compared within 
the same population and the outcome was categorized as “increase” 
if the post- treatment level was higher than the pre- treatment level, 
and “decrease” if it was lower. There were seven observations that 
reported the exact same value of antibody isotype levels both pre- 
and post- treatment.10,26,27 The number of those observations were 
too small to form their own category “no change”; therefore, they 
were categorized into “decrease” group in this study for analyses pur-
poses. All observations were grouped according to the type of schis-
tosome parasite antigens (WWA or SEA) that were used to measure 
antibodies and analysed separately. Prior to the data stratification, 
we conducted preliminary analyses. The analyses results supported 
the partitioning by antigen type but not parasite species; therefore, 
WWA and SEA were analysed separately but not parasite species.
There were 29 observations from four articles that failed to re-
port pre- treatment infection intensity of study participants. In these 
cases, pre- treatment infection intensity was obtained from scientific 
publications describing the larger populations that contained the 
study populations (articles listed in Table S2). Similarly, there were 
three observations from two articles that did not report the schis-
tosome infection prevalence in the study area. In these cases, prev-
alence was obtained from scientific publications or governmental 
reports from the same area or larger area that contained the study 
populations (Table S2).
In schistosomiasis endemic areas, infection intensity peaks in the 
young age group, giving a convex curve typically observed in schis-
tosomiasis.28 Furthermore, our preliminary analyses using a mixed 
effects logistic regression model suggested that there is an associ-
ation between age and infection intensity (data not shown). To take 
this nonlinear association into account, a combination predictor for 
age and infection intensity was generated, with format age/infection 
F IGURE  1 A systematic review flow diagram. Diagram of the number of articles identified and examined at each stage of the review
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intensity as shown in Table 2. All of the observations were catego-
rized according to age/infection intensity categories. All predictors 
used for CART analysis are listed in Table 2.
2.6 | Classification and Regression Tree models
Classification and Regression Tree (CART) models were used to iden-
tify influential predictors of the direction of change of schistosome 
specific antibodies after PZQ treatment.29,30 Briefly, CART models are 
non- parametric and nonlinear analyses which allow us to investigate 
the pattern of data without making data distribution assumptions of 
both outcome and predictors.31 CART models do not make assump-
tion about the type of association between dependent variable and 
influential predictors.32 In addition, CART models do not have man-
datory minimal sample size that allows us to apply this model to study 
with a small sample sizes.32 Confidence intervals or standard errors 
are the most common weighting methods for meta- regression31 and 
for meta- CART.33 However, in this analysis the measures of antibody 
levels were ELISA OD values, which cannot be compared directly 
when coming from different research groups.25 Therefore, in this 
analysis, the sample size (the number of participants) was used for 
weighting. The number of participants across studies varied from 7 
to 148. The potential predictors used for the analysis were as follows: 
schistosome species (S mansoni, S haematobium, or co- infection), days 
between treatment and follow- up, and disease prevalence (low/mod-
erate or high), and age/infection intensity (child/low, adolescent/low, 
adult/low, child/high, adolescent/high, adult/high) (Table 2).
The CART analysis was conducted to build a tree using the stan-
dard three steps: (a) growing a maximum- sized tree with largest 
number of subgroups, (b) pruning the tree to generate subtrees and 
(c) identifying the optimal sized tree with the minimal risk estimate 
following the methodology of Breiman.30 Initially, the maximum- 
sized complex trees were grown with data from all study variables 
for each antibody isotype. All potential predictors were compared 
using	the	Gini	index	to	identify	the	optimum	split	of	the	dependent	
variable	 (increase	or	decrease	 in	antibody	 level).	Based	on	 the	Gini	
index, the strongest predictor variable and its splitting value, that is 
sub- groupings for categorical variables and cut- off values for contin-
uous variables, were used to split the original data (ie, root node) into 
two subgroups (ie, daughter nodes). The subgroups were then divided 
repeatedly into smaller subgroups following the same procedure until 
they represented the most homogeneous subgroups achievable (ie, 
terminal node). In this study, terminal nodes of these maximum- sized 
trees were set to be pure (ie, the node contents only “increase” or 
“decrease” observations) or with only a single observation. Then a se-
ries of subtrees was generated by pruning the initial maximum- sized 
trees. To estimate the optimal subtree among the different sized sub-
trees, 10- fold cross- validation analysis was conducted for each sub-
tree followed by the selection based on the one standard error (SE) 
rule. Briefly, the cross- validation analysis is used to estimate the risk 
of misclassification using a randomly selected subset (ie, test samples) 
of the original dataset (ie, learning sample). The optimal tree is the one 
that yields the minimal risk estimate. However, the noisy nature of the 
data and the instability of the cross- validation procedure can lead to 
the selection of unstable and large trees.34 Therefore, following the 
one SE rule, the smallest tree that has a cross- validation risk estimate 
of less or equal to the minimal risk plus one SE of the minimal error 
was selected as the optimal tree30,35 (Figures S1 and S2).
3  | RESULTS
Following a systematic review, a total of 92 observations from 26 
articles	 (published	 1988-	2013)	 met	 all	 inclusion	 criteria	 and	 were	
considered for the final meta- analysis. There was a high degree of 
heterogeneity in the direction of change of antibodies (increase/
decrease) after PZQ treatment depending on population studied 
(Figure 2). The results showed a tendency towards an increase in 
anti- WWA antibodies, in contrast with no significant tendency or 
decrease in anti- SEA antibodies post- PZQ treatment (Figure 2). Five 
anti-	WWA	 antibody	 isotypes	 (IgA,	 IgE,	 IgG1,	 IgG2,	 IgG4)	 showed	
a significant trend of increase (X2 = 12.25, P < 0.001; X2 = 8.26, 
P = 0.004; X2 = 6.55, P = 0.011; X2 = 7.14, P = 0.008; X2 = 10.71, 
P = 0.001, respectively) (Figure 2). In contrast, two anti- SEA antibody 
Potential predictors 
(units) Codes
Prevalence (%) Low/Moderate High
<50 ≥50
Schistosome species S.m S.h Co- infection of 
S.m and S.h
Days after chemotherapy 
(days)
Continuous (14- 180 days)
Agea/infection intensityb Child/low Adolescent/low Adult/low
Child/high Adolescent/high Adult/high
S.m, S mansoni; S.h, S haematobium.
aAge	category:	child	(0-	10	y),	adolescent	(11-	20	y),	adult	(≥21).	
bInfection intensity: S mansoni:	Light	1-	99	eggs/1	g	faeces,	Heavy	≥100	eggs/1	g	faeces,	S haemato-
bium:	Light	1-	49	eggs/10	mL	urine,	Heavy	≥50	eggs/10	mL	urine.	
TABLE  2 List of potential predictors 
investigated and their measurement units/
codes
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isotypes	(IgG,	IgM)	showed	a	significant	trend	of	decrease	after	PZQ	
treatment (X2 = 8.07, P = 0.005; X2 = 4.48, P	=	0.034,	 respectively)	
(Figure 2). The CART used to determine predictors of antibody level 
change identified age/infection intensity as the most common factor 
affecting post- treatment change. Thus, the analysis identified optimal 
trees	for	anti-	SEA	(IgA,	IgE,	IgG1,	IgG2,	IgM)	and	for	anti-	WWA	(IgG,	
IgM)	(Table	3).	On	the	other	hand,	none	of	the	predictors	included	in	
the	analyses	had	a	significant	overall	effect	on	anti-	SEA	(IgG3,	IgG4,	
IgG)	and	anti-	WWA	(IgA,	IgE,	IgG1,	IgG2,	IgG3,	IgG4)	(Table	3).
The first split from the root node of anti- SEA IgE was based on 
the number of days post-PZQ treatment. The proportion of obser-
vations that reported increases of anti- SEA IgE less than 46 days 
after PZQ treatment was 88%, while only 17% of observations re-
ported increases more than 46 days after PZQ treatment (panel B 
in	Figure	3).	This	result	suggests	that	there	 is	transient	 increase	of	
anti- SEA IgE followed by a decrease to below pre- treatment levels.
The composite predictor age/infection intensity was identified 
as the most influential variable for direction of change for anti- 
SEA	antibodies	(IgA,	IgG1,	IgG2,	IgM)	and	for	anti-	WWA	(IgG,	IgM)	
antibodies	 (panels	 A,	 C,	 D,	 E	 in	 Figures	3	 and	 4).	 Anti-	SEA	 IgG1	
showed a tendency to a decrease among adolescents and adults 
with high pre- treatment infection but an increase among all other 
age and infection intensity groups (panel B in Figure 5). Anti- WWA 
IgG	showed	the	 tendency	 to	a	decrease	among	children	and	ado-
lescents with low pre- treatment infection intensity but an increase 
among all other age and infection intensity groups (panel D in 
Figure 5). The CART results showed the tendency of anti- SEA (IgA, 
IgM) and anti- WWA IgM to increase among children and adults, but 
decrease among adolescents regardless of their pre- treatment in-
fection intensity (panel A in Figure 5). Similarly, the results showed 
a	 tendency	 of	 anti-	SEA	 IgG2	 to	 decrease	 among	 adolescents	 and	
increase among children regardless of their pre- treatment infection 
intensity.	 In	 addition,	 the	 results	 also	 showed	 that	 anti-	SEA	 IgG2	
tends to increase among adults with low pre- treatment infection 
intensity but decrease among adults with high pre- treatment in-
fection intensity (panel C in Figure 2). Overall, changes in levels of 
anti-	SEA	IgG1,	IgG2	and	anti-	WWA	IgG	after	PZQ	treatment	were	
influenced by the combination of age and pre- treatment infection 
intensity. On the other hand, anti- SEA IgA, IgM and anti- WWA IgM 
were influenced by age only (Figure 5).
4  | DISCUSSION
Praziquantel (PZQ) is currently the recommended drug for treat-
ment of schistosomiasis.1 Immunology field studies have reported 
that PZQ treatment can enhance the development of host protec-
tive immunity against future re- infection.28,36 Schistosome parasite- 
specific antibodies are thought to play an important role in this 
protective immunity.37-39 As schistosomiasis endemic areas see 
increasing PZQ treatment in Mass Drug Administration (MDA) pro-
grams, it is important to determine any patterns in population- wide 
changes in immune responses and their drivers. Here, we conducted 
F I G U R E  2 The percentage of observations with increasing 
or decreasing levels of (A) anti- SEA, and (B) anti- WWA antibody 
isotypes after praziquantel treatment for eight antibody isotypes. 
The graph shows the fraction of observations that reported a 
decrease/no change (filled bar) or an increase (unfilled bar) in each 
antibody isotype. Chi- square tests were conducted for each pair 
of	anti-	SEA	or	anti-	WWA	antibody	isotype.	NS	non-	significant,	
*significant at p < 0.05, **significant at P < 0.01, ***significant at 
P < 0.001
TABLE  3 Predictors identified by the classification and 
regression tree model analyses
Predictors
Anti- SEA 
antibodies
Anti- WWA 
antibodies
Prevalence (%) - - 
Schistosome species - - 
Days after 
chemotherapy
IgE
Age/infection intensity IgA,	IgG1,	IgG2,	
IgM
IgG,	IgM
No	predictor:	mostly	
decrease
IgG3,	IgG4,	IgG - 
No	predictor:	mostly	
increase
- IgA,	IgE,	IgG1,	
IgG2,	IgG3,	IgG4
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a systematic review and meta- analysis to identify predictors that 
influence the direction of change in schistosome- specific antibody 
isotype levels after PZQ treatment in humans.
Our analyses showed that the antibodies’ direction of change 
after chemotherapy is highly variable among different populations. 
There was only single antibody isotype: anti- WWA IgA that have 
been reported to increase after PZQ treatment in all the human 
populations studied. Our analyses also showed that the antibod-
ies to whole worm antigens (WWA) being reported to increase in 
the majority of studies. In contrast, studies of anti- SEA antibody 
isotypes showed a weak tendency towards decreased levels after 
PZQ treatment. PZQ treatment has been reported to damage adult 
worm tegument, therefore allowing the host immune system to 
detect schistosome worm antigens that would otherwise not be 
accessible until those worms die naturally.5,15 This theory is in line 
with a previous report that PZQ treatment enhances the host im-
munological recognition of S haematobium specific proteins.15 The 
results of the present study are consistent with this hypothesis and 
that	 the	 elevation	 of	 some	 anti-	WWA	antibodies	 (IgA,	 IgE,	 IgG1,	
IgG2,	 IgG4)	 is	 less	 likely	 to	 be	 affected	 by	 characteristics	 of	 the	
populations.
There are multiple schistosome- specific antibodies whose as-
sociation with protection for schistosomiasis has been reported. 
In particular, schistosome specific IgE and IgA are commonly as-
sociated with protection against re- infection after PZQ treatment 
in humans.40-42 Ideally, vaccination programs would be the most 
effective	 control	 strategy	 for	 schistosomiasis.	 Nevertheless,	 al-
though a number of studies have been conducted to develop an 
F IGURE  3 Classification and 
Regression Tree Models identifying 
profiles of observations that had higher 
(increase) or lower (decrease/no change) 
anti- SEA antibody isotype levels after 
praziquantel treatment for (A) anti- SEA 
IgA,	(B)	anti-	SEA	IgE,	(C)	anti-	SEA	IgG1,	
(D)	anti-	SEA	IgG2	or	(E)	anti-	SEA	IgM.	
No	tree	was	obtained	for	the	remaining	
anti- SEA antibody isotypes. The hierarchy 
of the Classification and Regression Tree 
Model starts from the terminal nodes at 
the top. Abbreviations for age/infection 
intensity groups are listed in the text box 
and described in Table2
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effective vaccine for schistosomiasis, we still do not have any li-
censed schistosome vaccine. A review of animal studies has shown 
that attenuated schistosome parasite vaccines are more efficient 
than recombinant purified protein vaccines.43 One potential reason 
for this improved protection is that attenuated parasite vaccines 
expose hosts to a large variety of schistosome parasite antigens 
with a single vaccination and this strategy may provoke an over-
whelming response. Similarly, PZQ treatment and damage it does 
to the worm may release an equivalently large number of antigens 
that boost acquired protective immunity. Therefore, although the 
main purpose of PZQ treatment is to cure infected people, it is likely 
that a beneficial side effect is an increased protection against future 
re- infection. In line with this theory, our meta- analysis shows that 
indeed, both anti- WWA IgE and anti- WWA IgA are elevated after 
PZQ treatment in the majority (but not all) of study populations. 
Those reports together with our anti- WWA IgE and IgA results con-
firm the “booster” effect of PZQ treatment on a proposed correlate 
of acquired protective immunity among schistosome affected 
populations.
There are a number of studies that have reported the potential 
immunizing effect of PZQ treatment among affected populations. 
Nevertheless,	the	length	of	protection	that	could	be	induced	by	PZQ	
treatment remains unclear. Our analysis demonstrated the tendency 
for both anti- WWA IgE and anti- WWA IgA levels to be elevated 
during a 180- day period after treatment which suggests at least a 
6	month	protective	window.	Naus	et	al.	(1998)	conducted	an	immu-
nological study among Cameroonian children and found that anti- 
WWA IgE levels were elevated 1 month after the PZQ treatment 
but then became lower than pre- treatment baseline level 12 months 
after the treatment.44 That report together with our results indicates 
that the immunizing effect induced by PZQ treatment can last for 
as long as 6 months post- treatment, but may not last longer than 
12 months. Further epidemiological studies are therefore required 
to confirm the dynamics of anti- WWA IgE and IgA after PZQ treat-
ment to estimate the length of this induced protective immunity. 
These results also highlight the continuing need for the development 
of vaccines that can yield long- lasting protection and preclude infec-
tion as a requirement for immunity.
F IGURE  4 Classification and Regression Tree Models identifying profiles of observations that had higher (increase) or lower (decrease/no 
change)	anti-	WWA	antibody	isotype	levels	after	praziquantel	treatment	for	(A)	anti-	WWA	IgG	or	(B)	anti-	WWA	IgM.	No	tree	was	obtained	
for the remaining anti- WWA antibody isotypes. The hierarchy of the Classification and Regression Tree Model starts from the terminal 
nodes	at	the	top.	Abbreviations	for	age/infection	intensity	groups	are	as	listed	in	the	text	box	in	Fig	3,	also	described	in	Table	2
F IGURE  5 The influence of age and pre- treatment infection 
intensity for the direction of change of some antibody isotypes. The 
graph shows tendency of decrease (filled cell) or increase (unfilled 
cell) of each antibody isotype by age and pre- treatment infection 
intensity for (A) anti- SEA IgA, IgM, and anti- WWA IgM, (B) anti- SEA 
IgG1,	(C)	anti-	SEA	IgG2	and	(D)	anti-	WWA	IgG
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The analysis revealed a significant proportion of studies showing 
an	increase	rather	than	decrease	in	anti-	WWA	IgG4	(86%	of	obser-
vations reported increase) after treatment. Longitudinal and cross- 
sectional population studies have demonstrated the association of 
both	anti-	SEA	IgG4	and	anti-	WWA	IgG4	with	human	susceptibility	
to re- infection after treatment in schistosomiasis endemic areas.45,46 
In	particular,	 IgG4	has	been	suggested	as	a	possible	blocking	anti-
body that inhibits the action of protective IgE in both S haematobium 
and S mansoni infections.39,47,48 Field studies have reported that the 
ratio	of	IgE	to	IgG4	has	a	positive	influence	on	resistance	to	future	
S mansoni re- infection.49,50 There were multiple observations that 
reported	the	direction	of	change	for	both	IgE	and	IgG4	after	prazi-
quantel treatment. The half of those anti- SEA studies (nine observa-
tions) have reported the post- treatment increase of IgE and decrease 
of	IgG4,	supporting	the	immunizing	effect	of	praziquantel	treatment.	
On the other hand, the majority of anti- WWA studies reported the 
post-	treatment	increase	of	both	IgE	and	IgG4.	More	research	is	re-
quired to determine how the ratio of these two antibodies changes 
after chemotherapy, and how they relate to protection against 
re- infection.
The CART analysis results showed that for several antibody iso-
types, the direction of change after chemotherapy can be partially 
explained by a combination of the population’s age and pre- treatment 
infection intensity. Pre- treatment infection intensity determines the 
quantity of schistosome parasites’ antigens that participants are ex-
posed to following PZQ treatment. On the other hand, in endemic 
areas, participant age correlates with the cumulative history of ex-
posure to schistosome parasites.51 A study in baboons reported that 
attenuated schistosome parasite vaccines were effective regardless 
of the different schistosome infection history (naïve or infected then 
PZQ- treated).52 Supporting this, our results suggest that some iso-
types that offer putative protection against re- infection (anti- WWA 
IgA and IgE) are boosted by praziquantel treatment for a minimum 
of 6 months post treatment regardless of age. However, for other 
putatively protective isotypes (anti- SEA IgA) our results do indicate 
an effect of age. Overall, our result suggests that when schistosome 
parasite vaccine for human use becomes available, the effectiveness 
of the vaccine might be affected by not only vaccination dose but 
also by the age/infection history of participants. Effective vaccine 
development would benefit from investigating the immunological 
variability of the target human population.
There are limitations of the current study. First of all, CART 
analysis does not allow the random effects to be taken into ac-
count. Therefore, although multiple observations were extracted 
from a single article, random effect was not considered in the cur-
rent study. A preliminary analysis was conducted using mixed ef-
fects logistic regression models, which allowed random effect in 
the model. However, these models were not considered further. 
This was mainly because the majority of the models had very high 
information criterion values, indicating instability (results are not 
shown). Additionally, there are some previously identified candi-
date predictors such as sex21 and co- infection with human immu-
nodeficiency virus (HIV),22 which could not be considered in the 
current study due to the fact that only a limited number of reports 
were available.
This meta- analysis revealed that literature studies, on the 
whole, tended to report an increase of anti- WWA antibodies 
isotypes after PZQ treatment. Our analyses also show a consid-
erable variability in change among different antigens, antibody 
isotypes and populations following treatment with PZQ, confirm-
ing the work of Mutapi (2001).18 Although the combination of age 
and infection intensity, alongside the number of days after treat-
ment, were identified as influential predictors for some antibody 
isotypes, there is no single predictor that consistently affects all 
antibody isotypes in the same way. Our results also demonstrated 
that antibody isotypes that have been reported to have a protec-
tive effect against future re- infection (anti- WWA IgA, IgE) can be 
stimulated by PZQ treatment in the majority of cases for a mini-
mum of 6 months after treatment. These results, therefore, rein-
force previously reported protection enhancement following PZQ 
treatment.
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